Dihydrofolic acid reductase inhibitor

DRUG CLASS:

Dihydrofolic acid reductase inhibitor

News alerts, weekly reports and conference planners

Related drugs:

‹

methotrexate (37)

methotrexate oral solution (0)

ADX-2191 (0)

methotrexate IV (0)

methotrexate (37)

methotrexate oral solution (0)

ADX-2191 (0)

methotrexate IV (0)

›

No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	methotrexate Sensitive: A1 - Approval methotrexate Sensitive : A1	methotrexate Sensitive: A1 - Approval methotrexate Sensitive : A1
No biomarker	Oral Cancer	No biomarker	Oral Cancer	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	cytarabine + methotrexate Sensitive: A2 - Guideline cytarabine + methotrexate Sensitive : A2	cytarabine + methotrexate Sensitive: A2 - Guideline cytarabine + methotrexate Sensitive : A2
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Nasopharyngeal Carcinoma	No biomarker	Nasopharyngeal Carcinoma	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	cytarabine + methotrexate + idarubicin Sensitive: A2 - Guideline cytarabine + methotrexate + idarubicin Sensitive : A2	cytarabine + methotrexate + idarubicin Sensitive: A2 - Guideline cytarabine + methotrexate + idarubicin Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive: A2 - Guideline cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive : A2	cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive: A2 - Guideline cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive : A2	cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	ifosfamide + methotrexate + etoposide oral Sensitive: A2 - Guideline ifosfamide + methotrexate + etoposide oral Sensitive : A2	ifosfamide + methotrexate + etoposide oral Sensitive: A2 - Guideline ifosfamide + methotrexate + etoposide oral Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	cisplatin + doxorubicin hydrochloride + methotrexate Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + methotrexate Sensitive : A2	cisplatin + doxorubicin hydrochloride + methotrexate Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + methotrexate Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	methotrexate Resistant: A2 - Guideline methotrexate Resistant : A2	methotrexate Resistant: A2 - Guideline methotrexate Resistant : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	cytarabine + methotrexate + idarubicin hydrochloride Sensitive: A2 - Guideline cytarabine + methotrexate + idarubicin hydrochloride Sensitive : A2	cytarabine + methotrexate + idarubicin hydrochloride Sensitive: A2 - Guideline cytarabine + methotrexate + idarubicin hydrochloride Sensitive : A2
No biomarker	Lymphoma	No biomarker	Lymphoma	cytarabine + methotrexate + thiotepa Sensitive: A2 - Guideline cytarabine + methotrexate + thiotepa Sensitive : A2	cytarabine + methotrexate + thiotepa Sensitive: A2 - Guideline cytarabine + methotrexate + thiotepa Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	methotrexate + vinorelbine tartrate Sensitive: A2 - Guideline methotrexate + vinorelbine tartrate Sensitive : A2	methotrexate + vinorelbine tartrate Sensitive: A2 - Guideline methotrexate + vinorelbine tartrate Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	methotrexate + vinblastine Sensitive: A2 - Guideline methotrexate + vinblastine Sensitive : A2	methotrexate + vinblastine Sensitive: A2 - Guideline methotrexate + vinblastine Sensitive : A2
No biomarker	Leukemia	No biomarker	Leukemia	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
HER-2 negative	Breast Cancer	HER-2 negative	Breast Cancer	capecitabine + cyclophosphamide + methotrexate Sensitive: C2 – Inclusion Criteria capecitabine + cyclophosphamide + methotrexate Sensitive : C2	capecitabine + cyclophosphamide + methotrexate Sensitive: C2 – Inclusion Criteria capecitabine + cyclophosphamide + methotrexate Sensitive : C2
BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	methotrexate Sensitive: C3 – Early Trials methotrexate Sensitive : C3	methotrexate Sensitive: C3 – Early Trials methotrexate Sensitive : C3
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	cytarabine + methotrexate Resistant: C3 – Early Trials cytarabine + methotrexate Resistant : C3	cytarabine + methotrexate Resistant: C3 – Early Trials cytarabine + methotrexate Resistant : C3
BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	methotrexate Resistant: C3 – Early Trials methotrexate Resistant : C3	methotrexate Resistant: C3 – Early Trials methotrexate Resistant : C3
BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	cytarabine + methotrexate Resistant: C3 – Early Trials cytarabine + methotrexate Resistant : C3	cytarabine + methotrexate Resistant: C3 – Early Trials cytarabine + methotrexate Resistant : C3
CD5 positive	Diffuse Large B Cell Lymphoma	CD5 positive	Diffuse Large B Cell Lymphoma	methotrexate Sensitive: C3 – Early Trials methotrexate Sensitive : C3	methotrexate Sensitive: C3 – Early Trials methotrexate Sensitive : C3
CD79B mutation	Diffuse Large B Cell Lymphoma	CD79B mutation	Diffuse Large B Cell Lymphoma	methotrexate Sensitive: C3 – Early Trials methotrexate Sensitive : C3	methotrexate Sensitive: C3 – Early Trials methotrexate Sensitive : C3
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	methotrexate Sensitive: C3 – Early Trials methotrexate Sensitive : C3	methotrexate Sensitive: C3 – Early Trials methotrexate Sensitive : C3

Dihydrofolic acid reductase inhibitor

Dihydrofolic acid reductase inhibitor

Associations(37)

Associations
(37)